Answers are grounded in this paper and cite their sources.
Vaccine platforms are validated, adaptable technologies designed to enable a 'plug-and-play' approach to vaccine development and deployment, and have emerged as a cornerstone for epidemic and pandemic preparedness due to their capacity to be rapidly tailored to emerging pathogens. This capability was demonstrated during the COVID-19 pandemic, when the first clinical trial of a SARS-CoV-2 vaccine was initiated just 66 days after the viral genome was published. However, outbreaks caused by novel emerging viruses like SARS-CoV-2 are less common than those caused by known, re-emerging pathogens, including Marburg, Nipah and Lassa viruses. Unlike SARS-CoV-2, these pathogens have been recognised as public health threats for decades, yet licensed vaccines against them have yet to be realised. While this gap is partly attributable to scientific shortfalls, a more significant factor has arguably been the combination of economic, regulatory and epidemiological challenges that have impeded vaccine licensure and stockpile establishment. This review discusses how vaccine platforms are addressing some of these challenges, potentially providing the foundation for much-needed vaccine stockpiling approaches against re-emerging pathogens.
No takes yet. Share an insight, caveat, or question.
Jones et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: